研究疾病:
|
银屑病
|
研究疾病代码:
|
|
Target disease:
|
Psoriasis
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
银屑病是一种由免疫介导的、与遗传和环境因素相关的,主要累及皮肤和关节的疾病。世界范围内流行率约为2%[1]。本病给个人、家庭和社会带来沉重的身-心双重负担[2,3]。传统治疗手段较少,疗效有限而新兴生物制剂价格昂贵、副作用未知[4],限制了其临床应用。
中医药运用雷公藤治疗本病是半个世纪以来的重大进展,目前,中医研究多集中于雷公藤及雷公藤多甙片、雷公藤红素等单体和剂型的内服治疗[5]。研究表明,雷公藤能够抑制咪喹莫特诱导的小鼠银屑病模型中TNF-α和IL-17A的表达[6],能够降低EAE模型中的T细胞和DC共培养后的炎症因子的分泌[7],这些都说明雷公藤对银屑病的治疗作用,是一个十分有希望和前途的药物。本着中医“外治之理即内治之理”的观点,我们拟采用国际通行的临床研究准则,采取随机、对照、双盲双模拟的规范研究方法,系统展开雷公藤颗粒剂湿敷外用治疗银屑病血热证临床研究。为进一步研究和应用打下坚实的基础。雷公藤颗粒剂湿敷外用治疗银屑病血热证的临床研究,既能体现与完善中医“外治之理即内治之理”之原则,也为进一步开发中医药外用制剂打下坚实的基础,更为治疗银屑病,特别是外用法治疗银屑病提供了新的思路和方向。
|
Objectives of Study:
|
Psoriasis is an immune-mediated, genetic and environmental disease that primarily affects the skin and joints.Worldwide prevalence is about 2%[1].This disease brings a heavy physical and mental burden to individuals, families and society[2,3].Traditional treatment methods are few, with limited efficacy, while emerging biological agents are expensive and have unknown side effects[4], which limit their clinical application.
TCM application of tripterygium wilfordii in the treatment of this disease is a major progress in half a century. At present, TCM studies mostly focus on the internal administration of monomers and dosage forms such as tripterygium wilfordii, tripterygium glycosides tablets and tripterygium wilfordii[5].Studies have shown that Tripterygium wilfordii can inhibit the expression of TNF-α and IL-17A in imiquimode-induced mouse psoriasis model[6], and can reduce the secretion of inflammatory cytokines after co-culture of T cells and DC in EAE model [7]. All these indicate that Tripterygium wilfordii is a promising and promising drug for the treatment of psoriasis.Based on the viewpoint of "the principle of external treatment is the principle of internal treatment" in traditional Chinese medicine, we plan to systematically conduct a clinical study on wet application of Tripterygium wilfordii granules in the treatment of blood heat syndrome of psoriasis by adopting the internationally accepted clinical research criteria and adopting the standard research method of randomized, controlled, double-blind and double-simulation.It lays a solid foundation for further research and application.The clinical study of wet application of Tripterygium wilfordii granules in the treatment of psoriasis blood heat syndrome can not only reflect and perfect the principle of "external treatment is internal treatment", but also lay a solid foundation for the further development of external preparations of Chinese medicine, and provide a new way of thinking and direction for the treatment of psoriasis, especially for external treatment of psoriasis.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
1. 符合寻常型银屑病的西医诊断标准,皮损面积≤10%BSA,皮损倾向聚集型;
2. 符合血热证的中医证型诊断标准;
3. 年龄≥18岁,且≤79岁,性别不限;
4. 知情同意,患者签署知情同意书,通过伦理委员会讨论,志愿接受治疗、观察和各项检查者。
|
Inclusion criteria
|
The results were as follows: 1. The patients who met the diagnostic criteria of psoriasis vulgaris with skin lesion area less than or equal to 10% BSA tended to be aggregated;
2. Subjects who meet the diagnostic criteria of blood heat syndrome of traditional Chinese medicine;
3. Subjects aged >= 18 and <= 79 years, regardless of gender;
4. Patients with informed consent, signed informed consent, discussed through ethics committee, volunteered to receive treatment, observation and examination.
|
排除标准:
|
1. 仅有头面部皮损的患者,点滴型等皮损过于分散的患者,有其他活动性皮肤疾病可能影响病情评估者;
2. 3个月内曾系统接受研究性药物、生物制剂及免疫抑制剂治疗;2周内曾接受外用糖皮质激素、光疗治疗;
3. 处于严重的难以控制的局部或全身急、慢性感染期间,恶性肿瘤病史者以及原发或继发性免疫缺陷及超敏患者,有严重系统性疾病,具有严重精神病史或家族史者,或其他异常研究者判断不适合参与此试验的患者;
4. 8周内曾接受重大手术或研究期间将需要接受此类手术;
5. 妊娠或哺乳期女性;
6. 有酗酒、吸毒或药物滥用史者;
7. 已知对雷公藤或卡泊三醇成分过敏者,钙代谢失调者;
8. 其他原因研究者认为不合适参加本研究者。
|
Exclusion criteria:
|
1. Patients with only head and face lesions, patients with scattered lesions such as drip type, and patients with other active skin diseases may affect the condition evaluators;
2. Patients who received systemic research drugs, biological agents and immunosuppressants within 3 months; He had been treated with glucocorticoid and phototherapy within 2 weeks;
3. Patients in the period of severe uncontrollable local or systemic acute or chronic infection, patients with history of malignant tumor, patients with primary or secondary immunodeficiency and hypersensitivity, patients with severe systemic diseases, patients with severe mental history or family history, or other abnormal patients judged by researchers not suitable for this trial;
4. Patients who have undergone major surgery within 8 weeks or who will need such surgery during the study period;
5. Pregnant or lactating women;
6. Subjects with a history of alcohol, drug or drug abuse;
7. Subjects known to be allergic to Tripterygium wilfordii or calcipotriol, and subjects with calcium metabolism disorder;
8. For other reasons, those subjects that the researchers think are not suitable to participate in this study.
|
研究实施时间:
Study execute time:
|
从From
2021-03-01
至To
2022-12-31
|
征募观察对象时间:
Recruiting time:
|
从From
2021-03-01
至To
2022-10-31
|